TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Patient Positioning in Lumbar Fusion Surgery and Its Impact on Spinal Sagittal Balance and Surgeon Satisfaction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults patients, aged between 18 and 65 years of age~* Patients undergoing lumbar fusion for degenerative conditions~Exclusion Criteria:~* Patients \< 18 years of age or \> 65 years of age~* Patients who have a history of metastatic disease~* Patients who currently have a pending workman's compensation claim~* Patients who have had a previous spinal surgery~* Patients who have or have had a spinal infection~* Patients who have a spinal deformity, such as scoliosis~* Women who are pregnant~* Inpatients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Standard Positioning (Type: NO_INTERVENTION): None
- Hyperlordotic Positioning (Type: ACTIVE_COMPARATOR): Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness Ankle-7 Orthosis VS HAFO Orthosis on Gait in Diplegic CPChildren

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* - Clinical indication to the use of orthoses to improve the walking function confirmed by instrumental parameters obtained from analysis of the path (dynamic electromyography, optoelectronic stereophotogrammetry analysis);~* Patients who already have AFO orthoses (or ankle-7) that need to be renewed;~* Patients with new clinical indication to the use of orthoses but not yet in possession of the same;~* Informed consent from parents / guardians of the child~Exclusion Criteria:~* Cognitive disabilities that may affect the child's participation in the activities related to this study, in the opinion of the investigators;~* Lower limbs sensory disability that may affect any beneficial effects of the use of the orthoses, in the opinion of the investigators;~* Other diseases associated or not associated with PCI that, according to investigators, could affect the child's participation in the activities related to this study (eg: drug-resistant epilepsy);~* Administration of antispasmodic drugs in the last 6 months;~* Functional surgery of the lower limbs in the last 6 months;~* Indication for surgical treatment to be carried out within 6 months after the date of inclusion in the study.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- AFO - Ankle_7 group (Type: OTHER): AFO is active comparator, ANKLE7 is the experimental treatment
- Ankle-7 - AFO group (Type: OTHER): AFO is active comparator, ANKLE7 is the experimental treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Thermal Ablation Combined With External Beam Radiation Therapy for Patients With Inoperable Non-Small Cell Lung Cancer > 3.5 cm in Size

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with AJCC sixth edition Stage Ib or II non-small-cell lung cancer with cytology or biopsy proven disease and a minimum tumor size of 3.5 cm are eligible.~* To be considered node negative for N2 disease, patients will have mediastinal lymph nodes ≤ 1.5 cm and no clinically suspicious uptake on FDG PET in those areas.~* All patients are required to have been evaluated by a thoracic surgeon and have either refused surgery or been deemed medically inoperable due to co-morbid conditions.~* The CT images of the chest must be reviewed by an experienced interventional radiologist and the target lesion is determined to be in a location where RFA is technically achievable based on the proximity of adjacent organs and structures.~* Age ≥ 18 years old~* Performance Status 0-2 (ECOG)~Exclusion Criteria:~* History of prior malignancy within the past 2 years except for curatively treated basal cell carcinoma of the skin, cervical intra-epithelial neoplasia, T1N0 squamous cell carcinoma of the larynx, or localized prostate cancer with a current PSA of \< 1.0 mg/dL on 2 successive evaluations, at least 3 months apart, with the most recent evaluation no more than 4 weeks prior to entry~* Previous chest radiation to the region of interest.~* Pregnant or lactating women.~* A clinical diagnosis of bronchoalveolar carcinoma (BAC) will be made for patients in whom tissue diagnosis is by cytology alone with adenocarcinoma shown and the following radiographic criteria are met.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- thermal ablation with external beam radiation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: OCT-guided LALAK for KCN

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eyes with keratoconus that cannot be adequately or safely corrected with spectacles, contact lens or excimer laser surface ablation. The cornea must have healthy endothelium (endothelial cell density \> 1,500/mm2).~Exclusion Criteria:~1. Preoperative corneal thickness less than 400 microns.~2. Corneal edema~3. Central guttata~4. Inability to give informed consent.~5. Inability to maintain stable fixation for OCT imaging.~6. Inability to commit to required visits to complete the study.~7. Eyes with concurrent cataract, retinal diseases, glaucoma, or other eye conditions that may limit the visual outcome after surgery.~8. Patients with severe collagen vascular diseases or ocular surface disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- LALAK (Type: EXPERIMENTAL): laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.
- IEK (Type: ACTIVE_COMPARATOR): Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female over 1 years old~* Subject has confirmed diagnosis of Smith-Lemli-Opitz Syndrome~* Subject is currently receiving cholesterol supplementation~Exclusion Criteria:~* Subjects too ill to travel to the study site~* Subjects who are unable to safely undergo study procedures~* Pregnant women

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo
- Simvastatin (Type: EXPERIMENTAL): 0.5 mg/kg body weight/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically confirmed diagnosis of active atopic dermatitis (AD), according to the revised Hanifin and Rajka criteria~* 12-month history of AD and had no significant flares in AD for at least 4 weeks before screening~* inadequate response to a ≥1 month treatment with topical medications~* Atopic dermatitis covering ≥10% of the body surface area~* EASI score ≥16~* Validated Investigator Global Assessment (VIGA) ≥3~* Use of emollient(s) at least 2x daily for 1 week prior to baseline~* Negative coronavirus disease (COVID)-19 results at screening~Exclusion Criteria:~* Uncontrolled moderate-to-severe asthma~* Uncontrolled diabetes~* Stage III or IV cardiac failure~* Severe renal condition~* Major surgery within 8 weeks of screening~* Immunodeficiency and/or receipt of immunosuppressive drugs within 4 weeks of baseline~* Use of systemic Janus kinase (JAK) inhibitor within 8 weeks of baseline~* Received live or live-attenuated vaccine within 4 weeks of baseline~* Prior receipt of RPT193

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- RPT193 400 mg (Type: EXPERIMENTAL): RPT193 400 mg oral tablet administered daily for 16 weeks
- RPT193 200 mg (Type: EXPERIMENTAL): RPT193 200 mg oral tablet administered daily for 16 weeks
- RPT193 50 mg (Type: EXPERIMENTAL): RPT193 50 mg oral tablet administered daily for 16 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo oral tablet administered daily for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: The Influence of Pneumoperitoneum on Minimal Invasive Cardiac Output Measurements

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* all patients \>18 years scheduled for robot-assisted prostatectomy~* able to give informed consent~Exclusion Criteria:~* Patient with atrial fibrillation or other non-regular rhythm.~* Severe aorta/mitral stenosis~* Not able to give informed consent

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pneumoperitoneum and SVV/PPV (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Involvement of Transverso-sacral- Neo- Articulations or of Transverso-iliac Articulations in Chronic Lumbago

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult with age equal or above to 18.~* Subject affiliated to French health insurance (Sécurité Sociale)~* Lateralized lumbago on side of the neo-articulation evolving since more than 3 months~* Mechanical pain, lumbar low level or gluteal without sciatic irradiation (pain above the knee)~* Mean pain during the latest 24 hours above 4 on an analogic visual scale (from 0 to 10)- Pain induced by palpation in regards to the neo-articulation~* Pain not relieved by medical treatment with non steroids anti- inflammatory drugs or antalgics~* No clinical proof for a discal origin : inducing factor, impulsiveness, spinal syndrome, true Lasègue~* transverse-sacral abnormality of IIb, IIIa, IIIc or IV type with neo-articulation lateralized on side of pain~* Informed consent form signed~Exclusion Criteria:~* Age below 18~* Clinical arguments in favour of a discal origin~* Pregnant women or women that could become pregnant the day of the infiltration~* Diabetic patient~* Patient unable to understand the protocol~* No autonomy for coming to the hospital (no budget allocated for patient transportation)~* Hypersensitivity to local anesthetics with liaison amide~* Hypersensitivity to one of the components~* Porphyria- Local or generalized infection, suspiscion of infection~* Severe troubles of coagulation, anti-coagulant treatment taken~* Bilateral lumbago with bilateral neo-articulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- corticoid (Type: EXPERIMENTAL): Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
- physiological solution (Type: PLACEBO_COMPARATOR): Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Compensatory Reserve Index (CRI) for Management of COVID-19

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Eligible patients will be those who are:~* COVID-19 positive;~* Ages \> 18 and \< 70 years old;~* Require \> 2 liters of oxygen by nasal cannula to maintain SpO2 \> 90%;~* Are admitted to the sixth floor at University Hospital, on one of two designated Hospitalist services (approximately 16 COVID-19 positive patients/service).~Exclusion Criteria:~* COVID-19 negative~* Age \<18 or \>70 years~* On \<2 liters oxygen via nasal canula~* Pregnant~* Incarcerated~* DNR/DNI~* Decisionally Challenged

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CRI Monitoring/Management (Type: None): These patients are COVID-19 positive; ages \> 18 and \< 70 years old; require \> 2 liters of oxygen by nasal cannula to maintain SpO2 \> 90%; are admitted to the sixth floor at University Hospital, on one of two designated Hospitalist services (approximately 16 COVID-19 positive patients/service). Patients in the study cohort will also be monitored with a CipherOx CR T1 tablet in a continuous manner to determine if maintaining CRI vales between 0.9-0.7 will: 1) help guide IV fluid (e.g. crystalloid, colloids, blood products) and medication therapy (e.g. diuretics); 2) allows earlier identification of patients who are poorly compensating and will require ICU level care; 3) reduces AKI and/or need for CRRT; and 4) improves clinical outcomes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 - 65 years old~* Moderate pain defined as 4-6 out of 10, severe pain defined as ≥ 7 out of 10 as defined by the numeric rating pain scale (NRS)~* Proficient in reading and understanding English~* Are deemed by the attending physician to require opioid therapy.~Exclusion Criteria:~* Inability to give consent,~* Inability to use the numeric rating scale (NRS) score~* Long-term use of opioids, history of chronic pain~* Known substance abuse known as excessive use of a drug such as (e.g. alcohol, narcotics or cocaine)~* Known hypersensitivity to ketamine or fentanyl~* Pregnancy~* Alcohol intoxication~* Depression~* Anxiety~* Chronic obstructive pulmonary disease~* Asthma~* Cirrhosis~* On dialysis~* Acute ischemic stroke~* Heart rate (HR) less \< 60 bpm or \> 120 bpm~* Systolic blood pressure (SBP) \< 90 mmHg or \> 180 mmHg~* Ischemic heart disease~* Ketamine prior to arrival~* Trauma patients~* Sepsis or septic shock~* Weight \> 100 kg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Sub-Dissociative Ketamine alone (Type: ACTIVE_COMPARATOR): 0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
- Fentanyl alone (Type: ACTIVE_COMPARATOR): 1 mg/kg of Fentanyl IV administered over at least 1 minute
- Sub-dissociative Ketamine and Fentanyl (Type: EXPERIMENTAL): Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: This is a Single Ascending Dose Tolerance Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria~* BMI 18.0 to 28.0 kg/m2,~* systolic blood pressure 90-140 mmHg,~* diastolic blood pressure 50-90 mmHg,~* heart rate 50 100 beats/min (all inclusive),~* clinically normal safety ECG and laboratory results~Exclusion Criteria~* relevant disease,~* treated with SLV354 before

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- A1 (Type: EXPERIMENTAL): Part A, Parallel design Arm 1
- A2 (Type: EXPERIMENTAL): Part A, Parallel design Arm 2
- A3 (Type: EXPERIMENTAL): Part A, Parallel design Arm 3
- A4 (Type: EXPERIMENTAL): Part A, Parallel design Arm 4
- A5 (Type: EXPERIMENTAL): Part A, Parallel design Arm 5
- A6 (Type: EXPERIMENTAL): Part A, Parallel design Arm 6
- A7 (Type: EXPERIMENTAL): Part A, Parallel design Arm 7
- A8 (Type: EXPERIMENTAL): Part A, Parallel design Arm 8
- A9 (Type: PLACEBO_COMPARATOR): Part A, Parallel design Arm 9
- B1-1 (Type: EXPERIMENTAL): Part B, Cross-over design, Arm 1
- B1-2 (Type: EXPERIMENTAL): Part B, Cross-over design, Arm 2
- B2-1 (Type: EXPERIMENTAL): Part B, Cross-over design, Arm 3
- B2-2 (Type: EXPERIMENTAL): Part B, Cross-over design, Arm 4
- B3 (Type: PLACEBO_COMPARATOR): Part B, Cross-over design, Arm 5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Recurrent or metastatic breast or prostate cancer~* Pain worst score of 4 or greater on the Brief Pain Inventory~* No prior enrollment on this study (patients treated during the run-in period are ineligible for randomization)~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Menopausal status:~* Not specified~Performance status:~* ECOG 0-2~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* No major psychiatric illness, including the following DSM-III-R diagnoses:~  * Bipolar disorder~ * Schizophrenia~ * Major depression~ * Multiple personality disorder~ * Psychotic disorder~ * Dementia~ * Outpatient status required~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Not specified~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 28 days since prior palliative radiotherapy to major site(s) of pain~Surgery:~* Greater than 30 days since prior surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Observation (Type: ACTIVE_COMPARATOR): Standard pain management interventions usually given by hospital staff
- Educational Intervention and Behavioral Skills Training (Type: EXPERIMENTAL): Patients participated in a program including video presentations, written materials, and coaching in behavioral skills to improve pain control (not to reduce analgesic use).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for surgery to remove primary tumors in the pancreas, liver or colon and have not undergone any prior treatment~* Ability to understand and the willingness to sign a written informed consent~Exclusion Criteria:~* Pregnant women will not be consented~* Patients that are unable to consent for surgery~* Primary liver tumors with cirrhosis will be excluded from this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ancillary-correlative (tissue stiffness analysis) (Type: None): Patients undergo fresh tumor tissue collection at the time of surgery. The fresh tumor tissue samples are analyzed for tissue stiffness measurements using optical polarimeter device and cell viability using automated cell counter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues